Vepdegestrant
- Generic Name
- Vepdegestrant
A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT06275841
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2025-01-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT06256510
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 65
- Registration Number
- NCT06206837
- Locations
- 🇺🇸
Highlands Oncology, Rogers, Arkansas, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸Hoag Health Center Irvine, Irvine, California, United States
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 11
- Registration Number
- NCT06125522
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States
🇺🇸UCHealth Harmony, Fort Collins, Colorado, United States
A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy Participants
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT06005688
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT05732428
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳Jilin Province Tumor Hospital, Changchun, Jilin, China
🇨🇳The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT05673889
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 624
- Registration Number
- NCT05654623
- Locations
- 🇺🇸
Morton Plant Hospital - BayCare Health System, Clearwater, Florida, United States
🇺🇸3T Radiology LLC, Coconut Creek, Florida, United States
🇺🇸Florida Cancer Specialists - South, Fort Myers, Florida, United States
A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05652660
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 47
- Registration Number
- NCT05573555
- Locations
- 🇺🇸
Moffitt McKinley Hospital, Tampa, Florida, United States
🇺🇸Stanford Women's Cancer Center, Palo Alto, California, United States
🇺🇸UCSF Medical Center at Mission Bay, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.